As of July 13, 2026
One-sentence summary: Q32 Bio (QTTB), a small clinical-stage biotech focused on immune-modulating biologics for alopecia areata, experienced an extreme intraday stock surge of over 85% on July 13, 2026, following positive Phase 2 topline data for its lead candidate bempikibart, amid high volatility, improving analyst sentiment, and atypical positive TTM financial metrics for a pre-commercial company.
$20.79 (+$9.58 / +85.38%)
Previous Close: $11.21 | Open: $18.33 | Day's Range: $17.28 - $22.50 | 52-Week Range: $1.57 - $22.50
Market Cap: ~$352.45 million | Volume: ~26.5 million (vs. avg. 808k)
Source: Yahoo Finance (real-time as of ~3:40 PM EDT, July 13, 2026; prices fluctuate rapidly).
| Period | Return (as of 7/13/2026) | Notes |
|---|---|---|
| YTD | +526.07% | Fact from Yahoo Finance; driven by clinical progress |
| 1-Year | +681.41% | Fact; significant outperformance vs. S&P 500 (+19.93%) |
| 3-Year | +17.95% | Fact |
| 5-Year | +82.76% | Fact |
Interpretation: The stock has delivered exceptional returns primarily on anticipation and confirmation of clinical milestones in alopecia areata, though such gains in biotech are often followed by sharp corrections on any negative developments.
Uncertainty: Future performance depends heavily on regulatory progress, additional trial data, and commercialization potential; historical returns do not predict future results.
| Metric | Value | Source/Notes |
|---|---|---|
| Revenue (TTM) | $53.74 million | Yahoo Finance; fact (likely from collaborations or milestones) |
| Net Income (TTM) | $33.24 million | Yahoo Finance; EPS $2.78; fact but atypical for clinical-stage biotech |
| Profit Margin | 61.86% | Yahoo Finance; fact |
| Return on Assets (TTM) | 18.75% | Yahoo Finance; fact |
| Return on Equity (TTM) | 157.18% | Yahoo Finance; fact |
| Cash (most recent quarter) | ~$50.75 million | Yahoo Finance; earlier reports (e.g., Q3 2024) showed ~$89M with runway into mid-2026 |
| Debt/Equity | 29.46% | Yahoo Finance; fact |
| P/E (TTM) | 7.48 | Yahoo Finance; fact |
Interpretation: Positive net income and high margins are unusual for a clinical-stage biotech and may reflect non-recurring items such as licensing revenue, grants, or accounting adjustments rather than sustainable operations.
Uncertainty: Exact drivers of recent profitability not detailed in summaries; prior quarterly reports (e.g., Q1 2026) showed net losses of ~$7.6M.
Consensus: Moderate Buy / leaning Strong Buy (multiple firms)
| Analyst/Firm | Rating | Price Target | Date/Action |
|---|---|---|---|
| Oppenheimer | Outperform (Maintain) | $40 (raised from $20) | July 13, 2026 |
| Wells Fargo | Overweight (Upgrade) | $66 | July 13, 2026 |
| Mizuho | Outperform | $36 (raised from $14) | Recent (post-data) |
| Cantor Fitzgerald | Overweight | Not specified in summary | May 2026 (initiation) |
| HC Wainwright | Buy | $13 | May 2026 |
Average 1-Year Price Target (pre-surge consensus): ~$14.25 (range $10–$20+); recent upgrades significantly higher.
Interpretation: Analysts are highly bullish following the alopecia data readout, with substantial PT increases reflecting perceived de-risking of the lead asset.
Uncertainty: Ratings and targets can change quickly; extreme PTs (e.g., $66) may reflect short-term momentum rather than long-term fundamentals. Limited coverage (5 firms noted in some reports).
Interpretation: Revenue will depend on successful regulatory approval and market adoption of bempikibart or other pipeline candidates.
Uncertainty: No visibility into specific partnership deals or patient demographics at this stage.
Key peers in biotechnology/autoimmune/alopecia space (selected from market data):
| Company (Ticker) | Market Cap | Focus Area | Notes |
|---|---|---|---|
| Tyra Biosciences (TYRA) | ~$1.96B | Biotech (FGFR inhibitors, etc.) | Direct peer comparison in Yahoo data |
| Shattuck Labs (STTK) | ~$624M | Biotech (immuno-oncology/autoimmune) | Peer |
| Larimar Therapeutics (LRMR) | ~$389M | Biotech (rare diseases) | Peer |
| Oruka Therapeutics (ORKA) | ~$5.07B | Biotech | Peer |
| Others (e.g., SPRY, ZVRA, PHAT, DSGN) | Varies | Biopharma/gene therapy | Broader autoimmune/rare disease competitors |
Broader Context: Competition includes approved JAK inhibitors (e.g., from Pfizer, Eli Lilly) for alopecia areata; Q32 Bio differentiates via IL-7R mechanism.
Interpretation: QTTB is a small-cap player in a competitive space where clinical success and mechanism differentiation are critical.
Uncertainty: Exact competitive landscape evolves with new trial data and approvals; market caps and focuses are dynamic.
Fact: Q32 Bio Inc. is a clinical-stage biotechnology company developing novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases. Lead asset: Bempikibart (ADX-914), a fully human anti-IL-7Rα antagonist monoclonal antibody. Additional pipeline: complement inhibitors (e.g., ADX-096 for ophthalmology). Company Website | Yahoo Profile
Interpretation: Pipeline targets re-regulation of adaptive and innate immunity; success hinges on Phase 2/3 readouts.
Uncertainty: Detailed early history limited in public summaries; refer to SEC filings for full timeline.
Links for more information: Yahoo Finance | Company Site | Investor Relations | Nasdaq